Nicotine on its own is not harmless, and the strongest evidence for that does not come from smokers at all. It comes from people who take nicotine without burning anything.
If you have spent any time reading about quitting, you have met this sentence: nicotine is the addictive part, the smoke is the harmful part. It is one of the most repeated claims in the category, and it is half right in a way that makes it more misleading than a straightforward error would be.
Why the question is hard to answer from smokers
You cannot separate nicotine from smoke by studying smokers. Everything arrives together: nicotine, carbon monoxide, oxidants, particulates, and a long list of combustion products. Any health outcome you measure in a smoker is the result of all of it.
So the question needs a population that takes nicotine without combustion. That population exists, and it has been studied for decades in Scandinavia.
What the snus and pouch evidence shows
A 2026 review in the Journal of Internal Medicine examined the cardiovascular evidence on Swedish snus and on nicotine pouches, which deliver comparable nicotine without tobacco. Three things in it matter here.
The epidemiology suggests elevated cardiovascular mortality among snus users, and the most consistent signals are for fatal myocardial infarction and heart failure. Associations with new atherosclerotic events are more mixed. These are observational findings, so they describe an association rather than demonstrating cause.
The mechanisms the authors point to are nicotine pathways: sympathetic activation, endothelial dysfunction, and increased arterial stiffness. Meanwhile the evidence for risk driven by tobacco-specific nitrosamines is sparse, and nitrosamine levels in modern Swedish snus have fallen, which makes that explanation less likely.
Putting those together, the review's authors read the epidemiological and mechanistic evidence as suggesting that nicotine may be an important contributor to the cardiovascular risk observed among snus users. That is an inference, not a demonstrated cause: observational evidence of this kind does not establish nicotine as the sole or definitive driver. It is still the opposite of what the popular version of this claim implies.
The same review notes that nicotine pouches deliver comparable or higher systemic nicotine than snus, and that long-term cardiovascular outcome data for them does not exist yet.
One limit worth being explicit about: snus and pouches are not cigarettes, vapes, hookah or IQOS. This evidence tells you something about nicotine in the absence of combustion. It does not give you a risk figure for any product you are actually using, and we are not going to pretend it does.
It is also worth being precise about what kind of statement "primary driver" is. It is not a measurement. It is the authors' inference from three things pointing the same way: the outcome signals in the epidemiology, the mechanisms the review attributes to nicotine, and the weakness of the main competing explanation. Inferences like that can move. If the nitrosamine evidence strengthened, or if the cardiovascular signals turned out to track something snus users tend to do rather than the snus itself, the conclusion would weaken. Knowing which parts could move is more useful than memorising the verdict.
The cancer question, carefully
Nicotine has traditionally been described as non-carcinogenic, and that is where most popular accounts stop.
A 2026 systematic review in Food and Chemical Toxicology takes a narrower question: what nicotine does to p53 signalling pathways. It describes laboratory and mechanistic evidence, accumulated over roughly two decades, suggesting that nicotine may promote processes involved in cancer progression rather than initiating cancer itself. The review traces these pathways across lung, gastric, liver and cervical cancer, and finds the effect is context dependent.
Read that for what it is. These findings do not establish that nicotine use causes cancer in people, and they do not quantify any cancer risk from nicotine used without smoking. What they do is remove "nicotine is inert" from the list of things you can say with confidence.
What this does not mean
It does not mean smoke stops mattering. Nothing here suggests the combustion products are a minor part of the problem, and the honest comparison between smoking and vaping is a separate question we have answered separately.
It does not mean you should stop using nicotine replacement therapy. NRT should be used according to the product instructions and, where appropriate, advice from a healthcare professional, which is a different proposition from indefinite recreational nicotine. We have written about what the patch evidence actually shows. Anyone with concerns about a prescribed regimen should consult the prescriber before making changes.
And it does not mean the risk is distributed evenly. The figures above describe populations. They do not tell you your number.
Our view, not the review's
Here is our argument, labelled as ours because no study tested it.
The reason this particular claim travels so well is that it is useful. "Nicotine is the addictive part, smoke is the harmful part" lets someone move sideways, from cigarettes to a vape to a pouch, while keeping the thing that actually holds the habit in place. The belief does not reduce the dependence. It relocates it, and it gives the move the feeling of a decision about health.
That is the pattern we think matters more than the toxicology, and it is one of the beliefs most smokers are carrying without having chosen them.
It also explains why we do not organise the work around the molecule. Changing the delivery device may alter what else you are exposed to. On our reading it does not, by itself, address the behavioural cues and routines that hold nicotine dependence in place. What travels across the switch is the set of situations you have learned to expect relief in, and the account of yourself that comes with them. That is the part the seven days work on: noticing an urge instead of suppressing it, deciding in advance what you do when one arrives, and tracking who you are becoming rather than only how many days you have held.
Where Nicoxit comes in
Nicoxit is a seven-day journey, 31 modules, built on published behavioural science. It covers cigarettes, vapes, hookah and IQOS, and it treats the dependence rather than the delivery device, which is why switching forms does not get you out of it. You keep using while you work through it. That is deliberate, and it explains why.
Not medical advice.
References
- Olsson, M., Tønnesen, H., Hedberg, J., Sundström, J., Nordendahl, E., Klinge, B., Fored, M., Magnusson, C., Jönsson, D., Persson, P., & Naimi-Akbar, A. (2026). Snus, nicotine pouches and cardiovascular disease: Evidence, mechanisms, and the challenge of novel nicotine products. Journal of Internal Medicine. https://doi.org/10.1111/joim.70160
- Jiang, Q., Zhang, Z., Zhou, J., Zhou, T., & Wang, H. (2026). The role of p53-mediated signaling pathways in nicotine-induced cancer: A systematic review. Food and Chemical Toxicology, 215, 116215. https://doi.org/10.1016/j.fct.2026.116215
- Benowitz, N. L., Yang, H. Y., Jacob, P., & St Helen, G. (2025). Nicotine dosimetry in evaluating electronic cigarettes compared to cigarette smoking: Implications for tobacco regulatory science. Chemical Research in Toxicology, 38(4), 686–694. https://doi.org/10.1021/acs.chemrestox.4c00462
Frequently asked questions
Is nicotine bad for you if there is no tobacco in it?
The evidence that comes closest to answering this is from snus and nicotine pouch users. A 2026 review read the evidence as suggesting nicotine may be an important contributor to the cardiovascular risk observed among snus users, through sympathetic activation, endothelial dysfunction and arterial stiffness. Those are observational associations rather than established cause, and long-term outcome data for pouches does not exist yet.
Is nicotine a carcinogen?
It has traditionally been described as non-carcinogenic. A 2026 systematic review of p53 pathways describes laboratory evidence suggesting nicotine may promote processes involved in cancer progression rather than initiating cancer. That work does not establish that nicotine causes cancer in people and does not quantify a risk.
Is nicotine addictive on its own?
Yes, and it is the component most responsible for dependence. That is the part of the popular claim that holds up.
Does this mean vaping is as bad as smoking?
No, and this article does not make that comparison. Exposure and risk are two different claims, which we have set out separately.
Should I stop using nicotine gum or patches after reading this?
Not on the strength of an article. NRT is used over defined periods with a prescriber's guidance. Ask the person who prescribed it, and do not change a dose yourself.
